Beneficial effect of highly active antiretroviral therapy on the prognosis of AIDS-related systemic non-Hodgkin lymphomas

AIDS Research and Human Retroviruses

Volumn 21, Issue 3, 2005, Pages 214-220

  Lascaux, Anne Sophie ^a   Hemery, F ^a   Goujard, C ^b   Lesprit, P ^a   Delfraissy, J F ^b   Sobel, A ^a   Lepage, E ^a   Levy, Y ^a  

^a HENRI MONDOR HOSPITAL   (France)

^b BICÊTRE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; BLEOMYCIN; CD4 ANTIGEN; CYCLOPHOSPHAMIDE; DIDANOSINE; DOXORUBICIN; EFAVIRENZ; INDINAVIR; LAMIVUDINE; METHOTREXATE; NELFINAVIR; NEVIRAPINE; PREDNISOLONE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; VINDESINE; ZALCITABINE; ZIDOVUDINE;

ADULT; AIDS RELATED COMPLEX; ARTICLE; BONE MARROW CELL; CANCER COMBINATION CHEMOTHERAPY; CELL SURVIVAL; COHORT ANALYSIS; DRUG EFFECT; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; RISK BENEFIT ANALYSIS;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; FEMALE; HUMANS; LYMPHOMA, AIDS-RELATED; MALE; PROGNOSIS; RETROSPECTIVE STUDIES;

EID: 16444379213     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.2005.21.214     Document Type: Article

References (30)

1. Ledergerber B, Telenti A, and Egger M, for the Swiss HIV Cohort study: Risk of HIV related Kaposi's sarcoma and non-Hodgkin's lymphoma with potent antiretroviral therapy: Prospective cohort study. BMJ 1999;319:23-24.
2. Mocroft A, Katlama C, Johnson AM, Pradier C, Antunes F, Mulcahy F, et al.: AIDS across Europe 1994-98: The EuroSIDA study. Lancet 2000;356:291-296.
3. Ives NJ, Gazzard B, and Easterbrook PJ: The changing pattern of AIDS-defining illnesses with introduction of highly active antiretroviral therapy (HAART). J Infect 2001;42:134-139.
4. Besson C, Goubar A, Gabarre J, Rozenbaum W, Pialoux G, Châtelet FP, et al.: Changes in AIDS-related lymphoma since the era of highly active antiretroviral therapy. Blood 2001;98:2339-2344.
5. Kirk O, Pedersen C, Cozzi-Lepri A, Antunes F, Miller V, Gatell J, et al.: Non-Hodgkin lymphoma in HIV-infected patients in the era of highly active antiretroviral therapy. Blood 2001;98:3406-3412.
6. Eltom MA, Jemal A, Mbulaiteye SM, Devesa SS, and Biggar RJ: Trends in Kaposi's sarcoma and non-Hodgkin's lymphoma incidence in the United States from 1973 through 1998. J Natl Cancer Inst 2002;94:1204-1210.
7. Grulich AE, Li Y, McDonald AM, Correll PK, Law MG, and Kaldor JM: Decreasing rates of Kaposi's sarcoma and non-Hodgkin's lymphoma in the era of potent combination antiretroviral therapy. AIDS 2001;15:629-633.
8. Wilde JT, Lee CA, Darby SC, Wan Kan S, Giangrande P, Phillips AN, et al.: The incidence of lymphoma in the UK haemophilia population between 1978 and 1999. AIDS 2002;16:1803-1807.
9. Levine A, Seneviratne L, Espina B, Wohl A, Tulpule A, Nathwani B, et al.: Evolving characteristics of AIDS-related lymphoma. Blood 2000;96:4084-4090.
10. Matthews G, Bower M, Mandalia S, Powles T, Nelson M, and Gazzard B: Changes in acquired immunodeficiency syndrome-related lymphoma since the introduction of highly active antiretroviral therapy. Blood 2000;96:2730-2734.
11. Tam H, Zhang ZF, Jacobson L, Margolick J, Chimiel, Rinaldo C, et al.: Effect of highly antiretroviral therapy on survival among HIV-infected men with Kaposi sarcoma or non-Hodgkin lymphoma. Int J Cancer 2002;98:916-922.
12. Powles T, Imami N, Nelson M, Gazzard B, and Bower M: Effects of combination chemotherapy and highly active antiretroviral therapy on immune parameters in HIV-1 associated lymphoma. AIDS 2002;16:531-536.
13. Antinori A, Cingolani A, Alba L, Ammassari A, Serraino D, Ciancio B, et al.: Better response to chemotherapy and prolonged survival in AIDS-related lymphomas responding to highly active antiretroviral therapy. AIDS 2001;15:1483-1491.
14. Vilchez R, Kozinetz C, Jorgensen J, Kroll M, and Butel J; AIDS-related non-Hodgkin's lymphoma at a large community program. AIDS Res Hum Retroviruses 2002;18:237-242.
15. Hoffmann C, Wolf E, Fätkenheuer G, Buhk T, Stoenr A, Plettenberg A, et al.: Response to highly active antiretroviral therapy strongly predicts outcome in patients with AIDS-related lymphoma. AIDS 2003;17:1521-1529.
16. Conti S, Masocco M, Pezzotti P, Toccaceli V, Vichi M, Boros S, et al.: Differential impact of combined antiretroviral therapy on the survival of Italian patients with specific AIDS-defining illnesses. J Acquir Immune Defic Syndr 2000;25:451-158.
17. Chow KU, Mitrou PS, Geduldig K, Helm EB, Hoelzer D, and Brodt HR: Changing incidence and survival in patients with aids-related non-Hodgkin's lymphomas in the era of highly active antiretroviral therapy (HAART). Leuk Lymphoma 2001;41:105-116.
18. Kaplan ES and Meier P: Non-parametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457.
19. Cox DR. Regression models and life tables. J Stat Soc 1972;53:187.
20. Evison J, Jost B, Ledergerber L, Jost L, Strasser F and Weber R. HIV-associated non-Hodgkin's lymphoma: Highly active antiretroviral therapy improves remission rate of chemotherapy. AIDS 1999;13:732-734.
21. Thiessard F, Morlat P, Marimoutou C, Labouyrie E, Ragnaud JM, Pellegrin JL, et al.: Prognostic factors after non-Hodgkin lymphoma in patients infected with human immunodeficiency virus. Cancer 2001;88:1696-1702.
22. Levine AM, Sullivan-Halley J, Pike MC, Rarick MU, Loureiro C, Bernstein-Singer M, etal.: Human immunodeficiency virus-related lymphoma-prognostic factors predictive of survival. Cancer 1991;68:2466-2472.
23. Gisselbrecht C, Oksenhendler E, Tirelli U, Lepage E, Gabarre J, Parcel JP, et al.: Human immunodeficiency virus-related lymphoma treatment with intensive combination chemotherapy. Am J Med 1993;95:188-196.
24. Straus DJ, Huang J, Testa MA, Levine AM, and Kaplan LD: Prognostic factors in the treatment of human immunodeficiency virus-associated non-Hodgkin's lymphoma: Analysis of AIDS clinical trials group protocol 142-low-dose versus standard-dose m-VACOD plus granulocyte-macrophage colony-stimulating factor. J Clin Oncol 1998;16:3601-3606.
25. Kaplan LD, Abrams DI, Feigal E, McGrath M, Kahn J, Neville P, et al.: AIDS-associated non-Hodgkin's lymphoma in San Francisco. JAMA 1989;261:719-724.
26. Tirelli U, Errante D, Carbone A, Gloghini A, and Vaccher E: Malignant lymphomas in patients with HIV infection. Leuk Lymphoma 1996;22:245-257.
27. Little RF, Gutierrez M, Jaffe ES, Pau A, Horne M, and Wilson W: HIV-associated non-Hodgkin lymphoma: Incidence, presentation and prognosis. JAMA 2001;285:1880-1885.
28. Meyer RM, Hryniuk WM, and Goodyear MD: The role of dose intensity in determining outcome in intermediate-grade non-Hodgkin's lymphoma. J Clin Oncol 1991;9:339-347.
29. Ziegler JL, Beckstead JA, Volberding PA, Abrams DI, Levine AM, Lukes RJ, et al.: Non-Hodgkin's lymphoma in 90 homosexual men. Relation to generalized lymphadenopathy and the acquired immunodeficiency syndrome. N Engl J Med 1984;311:565-570.
30. Roithmann S, Toledano M, Tourani JM, Raphael M, Gentilini M, Gastaut J, et al.: HIV-associated non-Hodgkin's lymphomas: Clinical characteristics and outcome. The experience of the French registry of HIV-associated tumors. Ann Oncol 1991;2:289-295.